A clinical trial for frontotemporal dementia with GRN mutations

Information for people with FTD and their caregivers


At AviadoBio, our mission is to transform the lives of people living with devastating neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

ASPIRE-FTD is an open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN.
In the study, AVB-101 will be delivered as a one-time treatment into the thalamus via a stereotactic neurosurgical procedure at expert neurosurgical centers throughout Europe and the United States.

AVB-101 is an investigational gene therapy that contains a correct (non-mutated) version of the GRN gene. It is designed to restore levels of progranulin in the brain, potentially slowing or stopping the progression of FTD-GRN.

People between the ages of 30 and 75, diagnosed with FTD and a confirmed GRN mutation will be included in this study.

There are other criteria that determine eligibility, which may be discussed with a healthcare provider.

AviadoBio policy on expanded access to investigational therapies